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Abstract
In ecology, ‘‘disease tolerance’’ is defined as an evolutionary strategy of hosts against pathogens, characterized by reduced
or absent pathogenesis despite high pathogen load. To our knowledge, tolerance has to date not been quantified and
disentangled from host resistance to disease in any clinically relevant human infection. Using data from the Swiss HIV
Cohort Study, we investigated if there is variation in tolerance to HIV in humans and if this variation is associated with
polymorphisms in the human genome. In particular, we tested for associations between tolerance and alleles of the Human
Leukocyte Antigen (HLA) genes, the CC chemokine receptor 5 (CCR5), the age at which individuals were infected, and their
sex. We found that HLA-B alleles associated with better HIV control do not confer tolerance. The slower disease progression
associated with these alleles can be fully attributed to the extent of viral load reduction in carriers. However, we observed
that tolerance significantly varies across HLA-B genotypes with a relative standard deviation of 34%. Furthermore, we found
that HLA-B homozygotes are less tolerant than heterozygotes. Lastly, tolerance was observed to decrease with age, resulting
in a 1.7-fold difference in disease progression between 20 and 60-y-old individuals with the same viral load. Thus, disease
tolerance is a feature of infection with HIV, and the identification of the mechanisms involved may pave the way to a better
understanding of pathogenesis.
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Introduction
In response to pressure by pathogens, host populations can evolve
in two ways: They can develop either resistance or tolerance to the
disease [1–8]. Resistance mechanisms reduce the pathogen burden.
Tolerance mechanisms, in contrast, reduce the damage that
accompanies infection without affecting the pathogen directly.
One of the best examples for tolerance are sooty mangabeys
infected with Simian Immunodeficiency Virus (SIV), which—
despite harboring high virus loads—do not develop disease [9].
Whether hosts evolve resistance or tolerance affects the
evolutionary trajectory of host-pathogen systems [2,3,10–12].
The evolution of resistance genes in the host provokes counter-
adaptations of the pathogen that overcome host resistance,
resulting in an endless arms race. In contrast, tolerance genes
benefit both the host and the pathogen and are therefore predicted
to fix.
It is increasingly recognized that disentangling resistance and
tolerance not only advances our understanding of the coevolution
between hosts and pathogens but also is relevant clinically [13].
Like resistance factors, mechanisms of tolerance, once identified,
can be exploited for therapy. In contrast to resistance-based
therapy, tolerance-based treatment does not aim at reducing the
pathogen load but rather at ensuring the well-being of the host.
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For that reason, tolerance-based therapy is also hypothesized to be
evolution-proof—that is, not to select for drug-resistant pathogens
[4,5,14]. It has been argued, however, that the pathogen
population might evolve higher virulence in response to toler-
ance-based treatment [3,15,16].
Although numerous review papers have been written on the
potential benefits of tolerance research [1–8], the formal
framework for disentangling tolerance and resistance has not been
applied to many animal disease systems. There is a paradigmatic
study on mouse malaria [17] and a few on insects [18–20]. But a
quantitative tolerance analysis has, to our knowledge, not yet been
conducted for any clinically relevant human disease. In this study,
we apply such an analysis to HIV infection in humans.
Formally, tolerance can be quantified as the change in disease
progression across different levels of pathogen burden (see
Figure 1A) [2,4]. In the context of HIV, excellent measures of
disease progression and pathogen burden are available (see
Figures 1B and 2A). A few weeks after infection, HIV attains a
level in the plasma of infected individuals that is approximately
stable over several years. This level, called the set-point viral load,
is very well suited as a proxy for the ‘‘parasite burden’’ necessary
for a formal tolerance analysis.
The rate of disease progression—the second essential parameter
for an analysis of tolerance—can be measured quantitatively by
the decline of CD4+ T lymphocytes. Before infection, individuals
have on average 1,000 CD4+ T cells per ml of blood. A decline of
CD4+ T cells below 200 per ml of blood defines AIDS. Thus, the
decline of CD4+ T cells reflects what we know about the
mechanistic basis of the disease. CD4+ T-cell declines have also
been found to be independent predictors of disease progression in
the Swiss HIV Cohort [21] that we analyzed here and other
cohorts [22]. Importantly, the rate of decline can be calculated in a
much shorter time scale than the direct observation of disease
progression requires. The faster the CD4+ T cells decline, the
higher the rate of progression toward disease and death—that is,
the higher the virulence of the infection in the sense of
evolutionary ecology. For these reasons, also previous studies on
virulence relied on the CD4+ T-cell decline [23]. To our
knowledge, such a well-established, quantitative measure of
virulence is not available for any other human infection.
Results
We determined set-point viral loads and CD4+ T cell declines
in 3,036 HIV-1–infected individuals (see Figure 2, Materials and
Methods, and Data S1). To investigate tolerance of humans
against HIV, we determined the relationship between CD4+ T-
cell decline and set-point viral load in our study population. We
started by establishing this relation for the entire study population.
In subsequent analyses, this relationship served as a baseline,
against which we later compared the relationships between CD4+
T-cell decline and set-point viral load in specific subgroups.
Finally, we used the baseline relationship to define a tolerance
phenotype for each individual in our study population and
investigated if they are associated with single nucleotide polymor-
phisms (SNPs) in the human genome.
Tolerance Curve Is Nonlinear
To establish the baseline relationship between CD4+ T-cell
decline and viral load, we performed a regression analysis. We
found that this relationship is significantly nonlinear (see Figure 2).
Although nonlinear tolerance curves are a departure from what
has been reported in other systems, this finding is not surprising.
Linearity is an assumption generally adopted in regression analyses
mostly for the sake of simplicity and convenience. Commonly, low
sample sizes precluded the assessment of a potential nonlinearity.
The establishment of such a nonlinearity in the context of
tolerance, however, is particularly crucial to reliably establish
tolerance differences between groups [24].
The relationship is best described by a quadratic relationship
(see Figure 2B and Text S1). The intercept of the relationship is
not significantly different from 0. This is in line with the
expectation that uninfected individuals should have relatively
stable CD4+ T-cell counts. Also the linear term is not significantly
different from 0.
Mathematically, we can write the relationship as:
DCD4~a( log10 V )
2: ð1Þ
In this equation, DCD4 denotes the rate of change of CD4+ T
cells per ml of blood per day, and log10 V the logarithm to the base
10 of the viral load per ml of plasma. The quadratic model explains
5% of the variation in CD4+ T-cell decline, consistent with previous
studies investigating this relationship with linear models [25].
The parameter a is the quantitative measure of the average
tolerance across the entire study population, which we used in the
present study. It describes how the relationship curves downwards;
that is, it measures how the decline in CD4+ T cells, DCD4—a
surrogate measure of disease progression—changes with the set-
point viral load. For a value a= 0, CD4+ T cells would not decline
irrespective of the set-point viral load. This case would correspond
to complete tolerance. If a,0, an increase in the set-point viral
load accelerates the progression towards disease. The lower a, the
lower the tolerance. For the entire study population, we estimated
a=20.011160.0003.
Four individuals with an infection characterized by very high
viral load and minimal disease progression are also depicted in
Figure 2B. They lie above the average tolerance curve. These
individuals, referred to as viremic nonprogressors [26], share the
transcriptomic, interferon response, and gut microbial transloca-
tion profile of nonpathogenic SIV infection in their natural host
species [26–28]. Thus, the tolerance analysis correctly identified
individuals whose tolerance had been previously established.
Tolerance, Sex, and Age
First we tested if the tolerance parameter differs with sex and the
age at which individuals were infected. Information on these
Author Summary
When confronted with pathogens, hosts can either evolve
to fight them or learn to live with them. The first of these
two strategies is called ‘‘resistance’’ and the second
‘‘tolerance’’. In the context of HIV, many genes conferring
resistance have been identified, but no tolerance genes are
known. Using statistical techniques originating from plant
ecology, we analyzed data from an HIV cohort to look for
differences in tolerance between HIV-infected individuals
and tested whether they go hand in hand with genetic
differences. We found that younger people are more
tolerant to HIV infection. We also observed that individuals
who carry two different alleles of HLA-B, an important
immunity gene, are more tolerant. These findings add to
our understanding of how hosts tolerate infections and
could open new avenues for treating infections.
Human Tolerance Against HIV
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demographic characteristics was available for all 3,036 individuals
in our study population (see Materials and Methods). Although
females had an almost 2-fold lower viral load set-point than males,
we did not find significant differences in tolerance between sexes,
either in a univariate analysis (F test: p= 0.69; Figure 3A) or in an
analysis adjusting for age difference between sexes (F test:
p= 0.45). This result challenges previous reports, according to
which females are less tolerant (see Discussion) [29].
The age at which individuals become infected with HIV,
however, was very strongly associated with tolerance (Figure 3B),
both in univariate (F test: p= 1029) and multivariate analyses
controlling for sex (F test: p,361028). According to this analysis,
at equivalent viral load, the disease progression rate of an
individual who contracts HIV at the age of 60 is 1.7-fold faster
than that of an individual becoming infected at the age of 20.
No Association of Tolerance with Known Resistance
Genes
Next, we investigated if the tolerance parameter a differs across
well-established human genetic polymorphisms associated with
HIV control and disease progression—that is, resistance to HIV in
the sense of evolutionary ecology. For more than 850 individuals
in our study population, information on HLA class I alleles and the
CC chemokine receptor 5 (CCR5) genotype was available (see
Materials and Methods).
In a first step, we focused on HLA-B alleles that have been
found to associate with lower viral load—that is, with resistance
[30]. We wondered if these alleles are also associated with
tolerance. We found that protective HLA-B alleles are not
associated with higher or lower tolerance in a univariate analysis
(F test: p= 0.40; Figure 3C). This is independent of how
stringently we define protective HLA-B alleles (see Materials and
Methods and Figure S2). Thus, the protection these alleles confer
can be fully attributed to the effect they have on viral load.
Higher HLA-C expression has been associated with better
control of HIV viremia and slower disease progression [31–33].
The expression level of HLA-C is reasonably predicted by classical
HLA-C alleles, which are in strong linkage disequilibrium with a
causal polymorphism in the 3’ untranslated region of HLA-C [33].
We could thus predict the HLA-C expression level for 850
individuals in our study population, of which 243, 434, and 173
had low, medium, and high expression, respectively. We found
Figure 1. Quantifying tolerance and resistance. (A) The tolerance of a group of individuals can be measured as the change of fitness across
varying levels of parasite burden. Fitness is inversely related to the virulence of the infection. The difference in resistance between groups can be
quantified simply as the difference in the mean parasite burden. (B) In the context of HIV, virulence can be quantified by measuring the CD4+ T-cell
decline in an infected individual, and the set-point viral load is a good proxy for the ‘‘parasite burden’’. (C) and (D) show conceivable outcomes of a
tolerance-resistance analysis for the HIV resistance genes, such as classic protective HLA-B alleles. In the scenario entitled ‘‘pure resistance’’ (C), the
reduction of viral load that the resistance genes confers fully explains the reduction in disease progression. Alternatively, resistance genes could
additionally confer tolerance, as shown in plot (D).
doi:10.1371/journal.pbio.1001951.g001
Human Tolerance Against HIV
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that the tolerance parameter a does not vary significantly with
HLA-C expression in a univariate analysis. We also did not find
any association of tolerance with protective HLA-B alleles and
predicted HLA-C expression in a multivariate analysis including
both factors together with sex and age at infection as covariates.
Another important polymorphism related to HIV acquisition
and disease progression is located in the gene coding for the
chemokine receptor CCR5. About 10% of Europeans carry a
CCR5 allele with a 32 base pair deletion (CCR5D32). Homozy-
gous individuals are almost completely resistant to infection, while
carriage of a single allele has been reported to be associated with
slightly lower set-point viral load and slower disease progression
[34]. We divided the fraction of our study population, for which
we had information on the CCR5 genotype, into individuals with
(n= 163, all heterozygous) and without (n= 699) CCR5D32.
There was no significant difference in tolerance between these
two groups in a univariate analysis. Again, we obtained the same
result in a multivariate analysis including sex and age at infection
as covariates.
Variation of Tolerance Associated with HLA-B
Combinations
The analyses above aimed at determining if known resistance
genes also induce tolerance. We found that they do not. But what
if there are yet unknown genes, unrelated to resistance, that confer
tolerance?
As first candidates for such tolerance genes, we considered
HLA-B alleles irrespective of their protectiveness. To assess if
there are differences in tolerance associated with HLA-B, we
adopted a mixed-effects modeling approach. We combined the
two HLA-B alleles of an individual into a genotype (see Materials
and Methods) obtaining 375 unique genotypes in our study
population. The frequency distribution of the combined HLA-B
genotypes is shown in Figure 4A.
In the mixed-effects models, we used HLA-B genotype as a
random effect. Specifically, we assumed the following relationship
between CD4+ T-cell decline, DCD4, and set-point viral load, V,
in a univariate analysis:
DCD4~(azah)(log10 V )
2: ð2Þ
The parameter a characterizes the average tolerance in our
study population, and ah denotes how the tolerance of genotype h
deviates from this average. We treated this parameter as a random
effect—which means that we did not estimate it for each genotype
but estimated the variance of its distribution (see Text S1).
We found significant variation in the random effect ah of HLA-
B genotypes. Compared to a model without this random effect
with a likelihood ratio test, we obtained a significance level of
p= 0.0002. This variance is illustrated in Figure 4B: across HLA-
B genotypes, tolerance differs approximately 2-fold and the
relative standard deviation (the standard deviation divided by
the absolute value of the mean) is 0.34. This variance in tolerances
translates into an approximately 1.7-fold difference in the rate of
disease progression for two randomly selected HLA-B genotype
groups. Restricting our analysis to genotypes represented by more
than one individual yields an even larger and more significant
random effect, and a multivariate analysis that includes sex and
age at infection as covariates shows that these two variables do not
confound our analysis (see Text S1).
Table 1 lists 5% (n= 18) of the HLA-B genotypes with the most
extreme tolerance as predicted by the mixed-effects model. The
values in Table 1 are best linear unbiased predictions [35], rather
than estimates of tolerance parameters for each combined HLA-B
genotype group, and should therefore be interpreted with care.
Figure S3 shows a histogram of the best linear unbiased
predictions of tolerance for the HLA-B genotypes.
As outlined in Text S1, we could not identify any association of
tolerance with particular HLA-B alleles, suggesting that the effects
of the two HLA-B alleles on tolerance depend on the specific
combination of HLA-B alleles, rather than just on the sum of their
Figure 2. Relationship between CD4+ T-cell decline and set-
point viral load in our study population. (A) Calculation of the set-
point viral load and CD4+ T-cell decline, illustrated for a single
individual. The set-point viral load (red line) is calculated as the
geometric mean of the viral load measurements (after primary infection
and before treatment). The decline of CD4+ T cells is determined as the
regression slope (blue line) of CD4+ T-cell counts against time. The
CD4+ T-cell counts and virus load measurements of three randomly
selected individuals are shown in Figure S1. (B) Nonlinear tolerance
curve characterizing the relationship between CD4+ T-cell decline and
set-point viral load in our study population (n= 3,036). The black line
shows the quadratic regression line. Blue crosses indicate individuals
that were identified as viremic nonprogressors in a previous study [26].
doi:10.1371/journal.pbio.1001951.g002
Human Tolerance Against HIV
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effect (see Figure S4). A case in point is the least tolerant genotype
group ‘‘3501/3501’’. Carriage of this allele (considering homo-
and heterozygotes together) is not associated with higher set-point
virus load, faster CD4+ T-cell decline, or lower tolerance. But
HLA-B*3501 homozygotes display the most extreme departure
from the average tolerance curve. This is due to a very fast CD4+
T-cell decline in two individuals in this genotype group.
HLA-B Homozygosity Is Associated with Lower Tolerance
To further explore the importance of HLA-B allele combination
on tolerance, we compared homozygous to heterozygous individ-
uals. Of the 923 individuals in our study population, for which we
have information on the HLA-B alleles they carry, 39 were
homozygous, displaying 14 unique genotypes. A regression
analysis of the CD4+ T-cell decline against set-point viral load
with HLA-B homozygosity as a covariate confirmed a significant
association of homozygosity with tolerance in univariate (F test:
p= 0.00016) and multivariate analysis including sex and age at
infection (F test: p= 0.00005).
Figure 3D depicts the difference in tolerance between hetero-
and homozygotes according to a univariate analysis. Homozygotes
have higher set-point viral loads than heterozygotes and are
therefore expected to display faster CD4+ T-cell declines.
Figure 3D, however, shows that the CD4+ T-cell decline is in
fact much faster in homozygotes than their set-point viral load
predicts. Quantitatively, the tolerance paramete a of homozygotes
is 20.019 (versus a=20.012 in heterozygotes). This difference in
the tolerance parameter translates into a 1.6-fold faster rate of
Figure 3. Investigating associations of tolerance with sex, age at infection, and HLA-B alleles. (A) Tolerance does not differ significantly
between sexes in a univariate analysis. (B) Young age at infection is strongly associated with tolerance. The data are plotted stratified by age. The
younger, the redder. The three curves show the relationships between set-point viral load and CD4+ T-cell decline when infected at age 20, 40, and
60. (C) Classic protective HLA-B alleles induce pure resistance. The tolerance curves do not differ significantly for individuals with (red, n= 416) and
without (blue, n=507) protective HLA-B alleles. Protectiveness is defined according to the data presented in table 1 of [30] (see Materials and
Methods). (D) HLA-B homozygosity is associated with tolerance. Homozygotes also have significantly higher set-point viral loads—that is, are more
resistant than heterozygotes.
doi:10.1371/journal.pbio.1001951.g003
Human Tolerance Against HIV
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disease progression of homozygotes compared to heterozygotes
with the same set-point viral load. The tolerance difference
between homo- and heterozygotes further supports the view that
the effect of HLA-B alleles is not additive and refines our
understanding of the well-established HLA-heterozygote advan-
tage with respect to set-point virus load and disease progression
[36,37].
No Trade-Off Between Tolerance and Resistance
In contrast to previous studies on tolerance and resistance [17],
we did not find a trade-off—that is, a negative correlation—
between resistance and tolerance across HLA-B genotype groups
(see Text S1). The lack of a correlation between tolerance and
resistance suggests that there are no mechanistic or genetic
constraints to display both traits. If both tolerance and resistance
mechanisms are costly, a trade-off could eventually evolve, but the
co-evolutionary history between humans and HIV may have been
too short for distinct resistant and tolerant lineages to separate.
However, we found a positive relation between tolerance and
resistance across age. As individuals get older they become less
tolerant and less resistant.
No Genome-Wide Association with Tolerance
We also looked for genome-wide associations with tolerance. To
this end, we defined a tolerance phenotype for each individual by
calculating the residual in a quadratic regression between an
individual’s CD4+ T-cell decline and viral load, controlling for the
age at infection (see Figure S5A). This analysis failed to identify
any SNPs associated with tolerance (Figure S5B). It is important to
note that this analysis, in addition to setting very stringent
requirements for significance by correcting for multiple testing,
also assumes additivity of allelic effects—that is, ignores a potential
heterozygote advantage.
Discussion
In summary, we presented the first formal tolerance analysis of a
clinically relevant human infection. HIV infection features well-
established measures of pathogen burden and disease progression
that are required for such an analysis. The analysis consistently
identified a subset of individuals that tolerate high viral load with
minimal disease progression—the so-called viremic nonprogres-
sors [26], whose biological profile (transcriptome, interferon
response, gut microbial translocation) is reminiscent of SIV
infection in sooty mangabeys [26–28].
But beyond this consistency with the tolerant profile of these
four individuals, adopting the evolutionary ecology framework for
tolerance allowed us to assign quantitative tolerance measures to
well-defined groups of individuals and to statistically compare
them. In addition to investigating age- and sex-related differences
in tolerance to HIV, we could, due to the wealth of information
available for individuals in the Swiss HIV Cohort Study, test for
potential associations with genes implicated in disease susceptibil-
ity and progression, such as HLA class I and CCR5.
The finding that there is no difference in tolerance between the
sexes challenges a previous report by Farzadegan et al. [29],
according to which females are less tolerant than males. Just like
Farzadegan et al., we found that females have significantly lower
viral loads, but do not differ in their disease progression. In
contrast to Farzadegan et al., however, this pattern did not result
in a significant difference in the relationship between disease
progression and set-point viral load. One reason for this
discrepancy may be that Farzadegan et al. used data on AIDS
diagnosis during a time window of observation, whereas we used
CD4+ T-cell decline to measure disease progression. Furthermore,
Farzadegan et al. performed a survival analysis, whereas we
performed a regression analysis. Lastly, in contrast to our analysis,
Farzadegan et al. did not adjust for the age at which individuals
became infected. For all these reasons, the previous and present
analyses are difficult to compare and the discrepancy remains
unresolved.
In all of the figures that show our data, it is apparent that the
relationship between the set-point viral load and CD4+ T-cell
decline is weak. The noise in this relation is entirely consistent with
previous studies [25] in which 5%–9% of the variation in the
CD4+ T-cell decline could be explained by the set-point viral load.
Figure 4. Variation of tolerance associated with HLA-B geno-
type. (A) Frequencies of the HLA-B genotypes in our study population
of 923 individuals. Approximately half of the genotypes are represented
by only one individual. (B) Visualizing the random effect of the mixed
effect modeling approach. Estimated tolerance curves for each HLA-B
genotype, based on best linear unbiased predictions, are shown. We
estimated a mean tolerance parameter a~{0:012 (red curve), and a
deviation of the random effects, ah , of sh~0:0040 (see Text S1).
doi:10.1371/journal.pbio.1001951.g004
Human Tolerance Against HIV
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The analysis we performed to identify variation in tolerance aimed
at detecting differences in this relationship between different
subgroups in our study population. Given how noisy this relation
is, it is remarkable that we could identify significant associations of
host factors with tolerance at all.
In our study, we considered the most important host genes but
disregarded the potential impact of virus genetics on tolerance.
The viruses harbored by the individuals in our study population
differ by subtype. Although viral subtypes are hypothesized to vary
in virulence, this effect is difficult to ascertain due to usually
unaccounted differences in the study populations [38]. However, a
large fraction of individuals in the Swiss HIV Cohort carry subtype
B virus [39,40]. We therefore do not expect the genetic variation
of the virus to confound our analysis.
The framework for investigating tolerance we adopted for this
study, despite its internal consistency, has its limits. The parasite
burden—central as the x-axis in our tolerance curve plots—is not
simply an external factor affecting virulence but will itself be
influenced by the host genotype and phenotype. If we had virus
dynamics models that described the entire course of HIV
infection, the relationship between virulence and virus load could
be mechanistically derived, and we would not have to rely on the
statistical approach adopted here. Such a comprehensive model
has, however, been elusive to date [41], mostly because the slow
depletion of CD4+ T cells cannot be accounted for by HIV
targeting and killing these cells. Rather, a generalized immune
activation in infected individuals is currently conceived to be at the
heart of the mechanisms of pathogenesis [42], and a straight-
forward relationship between set-point virus load and CD4+ T-cell
decline is unlikely to emerge from the probably complex dynamics.
Until a better dynamical understanding of HIV pathogenesis
emerges, the low power of the set-point virus load to predict the
CD4+ T decline [25] provides some justification of treating these
two entities as independent.
Our analysis implicates HLA-B in modulating tolerance. In
particular, we established a tolerance advantage of HLA-B
heterozygotes, providing an additional example of a benefit that
host diversity affords against pathogens [36,43–46]. Mechanisti-
cally, it is conceivable that certain HLA-B alleles cause faster
disease progression without increasing viral load by modulating
immunopathology, rather than leading to the killing of infected
cells by cytotoxicity. The higher tolerance of individuals, who
contracted HIV at a young age, is likely to be explained by the
higher thymic output of young individuals that can compensate
infection-related CD4+ T-cell loss [47]. Confirming or refuting
these hypothetical mechanisms will be an important direction of
future research on tolerance against HIV.
Materials and Methods
Ethics Statement
The Swiss HIV Cohort Study was approved by the local Ethics
Committees of all participating centers, and written informed
consent was obtained from the participants. This project was
approved by the Scientific Board of the SHCS as project 697.
Study Population
We used data from the Swiss HIV Cohort Study (www.shcs.ch)
[48]. Briefly, the study has enrolled more than 18,000 HIV-
infected individuals to date. Sociodemographic and behavioral
data are recorded at entry to the study, in particular year of birth,
gender, and the date of the last negative HIV test. Laboratory and
clinical data, including viral load and CD4+ T-cell count, are
obtained at each semiannual follow-up visit. Approximately 2,000
individuals have been genotyped in the context of previous
genome-wide association studies [31,49] and/or at loci relevant for
HIV acquisition and disease progression, such as those encoding
the Human Leukocyte Antigen (HLA) class I genes and CCR5.
We included individuals into our study, for whom viral load
measurements and CD4+ T-cell counts were available, to reliably
estimate the set-point viral load and CD4+ T-cell decline, as
defined below. We restricted our analysis to data obtained before
antiretroviral treatment because the relationship between CD4+
T-cell count and viral load is dramatically altered during
treatment. To exclude the primary infection period, during
which viral load and CD4+ T-cell count exhibit strong
fluctuations, we discarded results obtained during the first 90
days after the estimated date of infection. To exclude the late
phase of the infection, during which viral load increases and
fluctuates due to severe immunosuppression, we discarded
measurements obtained when the CD4+ T-cell count was below
100 per ml. Individuals were included if they had at least two
eligible viral load results and three eligible CD4+ T-cell
measurements at least 180 days apart.
After applying these inclusion criteria, our study population
comprised 3,036 individuals. For 837, 923, and 862 individuals,
we had information on the HLA-A, -B, and -C alleles,
respectively. The CCR5D32 genotype was available for 862
individuals, whereas 852 individuals had genome-wide genotyp-
ing results. Of the 923 individuals, for whom we had information
on the HLA-B alleles, a large majority of 850 were of European
ancestry.
Table 1. The nine most and the nine least tolerant HLA-B
genotypes.
HLA-B Genotype Tolerancea Frequencyb
0702/3901 20.0061 (most tolerant) 4
1501/3906 20.0063 1
1801/4403 20.0067 7
5301/5801 20.0077 2
1501/5001 20.0080 1
1801/5101 20.0082 10
4402/4402 20.0082 3
1801/4402 20.0089 4
3501/4501 20.0089 1
4002/4501 20.0164 1
1801/2705 20.0169 7
4403/4403 20.0172 1
1402/5001 20.0174 2
1801/4002 20.0179 1
4402/5001 20.0180 3
3503/5101 20.0180 7
1402/4403 20.0200 5
3501/3501 20.0235 (least tolerant) 3
aBest linear unbiased predictions of the tolerance parameter ah for each
genotype.
bNumber of individuals with the respective genotype among the 923
individuals studied.
doi:10.1371/journal.pbio.1001951.t001
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Calculation of Set-Point Viral Load, CD4+ T-Cell Decline,
and Definition of Subgroups
Set-point viral load was determined as the geometric mean of
the eligible viral load measurements in each individual. Non-
detectable viral loads were set to half the detection limit. The
change of CD4+ T-cell count over time was estimated as the slope
in a linear regression of CD4+ T-cell count against the date at
which they were determined. Data S1 provides estimates of the
set-point viral load and CD4+ T-cell declines for the 3,036
individuals included in our study.
We defined an HLA-B allele as ‘‘protective’’ if it has been found
to associate with better HIV control and slower disease
progression, according to table 1 of [30]. In addition, we adopted
alternative, more restrictive definitions, considering either only
HLA-B27 or 57, or only HLA-B*27:05 and *57:01 as protective
(see Figure S2).
The HLA-C expression levels of the individuals in our study
were predicted from the classical HLA-C alleles using data from
table S1 in Kulkarni et al. [33].
For each individual, a combined HLA-B genotype was defined
by concatenating and sorting the four-digit alleles they carry. An
example for a genotype thus defined is ‘‘0702/3501’’.
Statistical Analysis
The statistical analysis is comprehensively described in Text S1.
Here we just give a brief overview of the logic of our statistical
procedures.
We regressed the change in CD4+ T cells over time, DCD4,
against the set-point viral load, V, using a least-square fitting
algorithm assuming linear and nonlinear relationships. Sex, age at
infection, protectiveness of HLA-B alleles, carriage of CCR5D32,
predicted HLA-C expression levels, and HLA-B homozygosity
were included into the regression analysis as covariates either
individually or in combination.
Formally, we investigated the association of tolerance with a
binary factor, such as sex or the carriage of protective HLA-B
alleles, by decomposing the parameter a in the baseline model
(equation 1):
DCD4~(a0zgfactor)( log10 V )
2: ð3Þ
Hereby, a0 denotes the tolerance parameter for the subpopu-
lation without the factor, and gfactor an offset associated with the
factor. Multiple factors were included into the statistical model by
further decomposing the tolerance parameter: DCD4~(a0z
gfactor1zgfactor2z . . . )( log10 V )
2.
If a factor had more than two levels, one level was defined as the
baseline and an offset parameter was added for each alternative
level. This was the case for HLA-C expression, which can be
expressed at low, medium, and high levels. Consequently, the
models including HLA-C expression as a covariate feature two
offset parameters (gC{med and gC{hi—see Text S1). Age at
infection, a, being a continuous variable, was assumed to affect the
tolerance parameter linearly:
DCD4~(a0zc a)( log10 V )
2: ð4Þ
In this expression, a0 denotes the tolerance when contracting
HIV at age 0, and c describes the increase or decrease of tolerance
per life year.
We assessed if a covariate significantly affected tolerance in two
ways. First, we checked if the offset associated with the covariate
was significantly different from zero. Second, we compared the
models with and without the covariate with an F test or a
likelihood ratio test. In all cases, these two tests agreed. Each factor
was considered on its own in a univariate analysis and in
combination with the other factors in multivariate analyses (see
Text S1).
The coefficient of determination of a model, R2, was calculated
as one minus the ratio between the variance of residuals in the
respective model fit and the variance in DCD4 [50]. Note that,
because our models set the intercept to zero, the variance in DCD4
does not represent the residual sum of squares of any special cases
of our models—that is, of any model nested in our models.
Implementation
The inclusion criteria, calculation of set-point viral load and
CD4+ T-cell decline, as well as the model fitting and comparisons
were implemented and performed in the R language of statistical
computing [51]. Regression analysis was performed using the R-
functions lm() and, for the mixed effects models, lme() in the R-
package nlme(). The F tests and likelihood ratio tests were
performed using the R-function anova().
Genome-Wide Association Study
For the genome-wide association study, we assigned a tolerance
phenotype to 852 individuals in our study population, for whom
we had genomic information and who were of European ancestry.
This phenotype was calculated as the deviation of the individual’s
set-point viral load and CD4+ T-cell decline from the average
tolerance relationship of the population. Because the age at
infection was associated very strongly with tolerance, we calculated
the deviation from an age-controlled tolerance relationship (see
Figure S5A).
Study participants had been genotyped in the context of
previous studies [31,49] using Illumina 550 or 1 M chips, and
genome-wide SNPs were imputed using the 1000 Genomes
Project CEU panel as a reference. After quality control and
exclusion of nonvariable SNPs, seven million variants were
available for association testing. We used linear regression to test
for association between each SNP and the tolerance phenotype,
including sex and the coordinates of the first five principle
components of an EIGENSTRAT analysis [52] as covariates. We
used Bonferroni correction to control for multiple testing (p
threshold = 561028).
Supporting Information
Figure S1 CD4+ T-cell count and virus load measurements in
three randomly selected individuals from our study population.
The red lines show the mean of the virus load measurements. The
blue lines are the linear regression lines of CD4+ T-cell counts
against time.
(TIFF)
Figure S2 Alternative sets of protective HLA-B alleles and
tolerance. (A) Considering only HLA-B27 or 57 as protective, we
did not find differences in tolerance between individuals with and
without protective HLA-B alleles. (B) We reached the same
conclusion if we are even more restrictive and assume only HLA-
B*27:05 and *57:01 to be protective.
(TIFF)
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Figure S3 Distribution of the best linear unbiased predictions for
the tolerance parameters, ah, across HLA-B genotypes.
(TIFF)
Figure S4 Tolerance by HLA-B allele. The tolerance parame-
ters of genotypes containing an allele are plotted (transparent grey
dots). Homozygous genotypes are plotted transparent red. Alleles
are ordered by increasing mean tolerance of genotypes that
contain the allele (red bars). Blue bars show the median tolerance
for each allele. The variation in mean effects of each allele is
significantly lower than the tolerance variation across genotypes.
(TIFF)
Figure S5 Genome-wide association study. (A) The tolerance
phenotype for an individual is defined as the deviation of his/her
CD4+ T-cell decline from the average tolerance curve character-
izing his/her age class. Two individuals are shown (red and blue
dots), together with the tolerance curves (red and blue lines) for
people who contract HIV at the same age. In this example, the red
and blue individuals contracted HIV at the age of 42 and 20 years,
respectively. (B) Manhattan plot showing the p across seven million
SNPs. None of the p is above the significance level corrected for
multiple testing (dashed line).
(TIFF)
Data S1 Estimates of the set-point viral load and CD4+ T-cell
decline for the 3,036 individuals in our study population.
(TSV)
Text S1 Details on the statistical analyses. This document
contains a detailed description of the statistical analyses, the results
of which are presented in this article. It also describes additional
analyses we performed to corroborate our findings.
(PDF)
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